Skip to main content
HLB Therapeutics Co.,Ltd. logo

HLB Therapeutics Co.,Ltd. — Investor Relations & Filings

Ticker · 115450 ISIN · KR7115450009 KO Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2026-03-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 115450

About HLB Therapeutics Co.,Ltd.

https://hlbtherapeutics.co.kr/en/

HLB Therapeutics Co., Ltd. is a biopharmaceutical company specializing in the development of innovative, first-in-class drugs for rare and intractable diseases. The company's clinical-stage pipeline focuses on addressing unmet medical needs in ophthalmology and oncology. Key development programs include RGN-259, a therapeutic agent for Dry Eye Disease and Neurotrophic Keratopathy, and OKN-007 for the treatment of Glioblastoma Multiforme. Additionally, the company is advancing a Natural Killer (NK) cell therapy through late-stage clinical trials to provide new therapeutic options for patients.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (HLB Co., Ltd.) and special related parties in the issuer (HLB Therapeutics). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-03-10 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from HLB Therapeutics regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like convertible bonds, falls under the 'Capital/Financing Update' category.
2026-03-04 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for HLB Therapeutics. It contains the meeting date, location, agenda items (financial statements, board appointments, etc.), and information regarding proxy voting and electronic voting. This document is a standard proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and request their participation/votes. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-02-26 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (HLB Therapeutics) announcing a significant change in financial results (revenue or profit/loss structure exceeding 15% for large corporations or 30% for others). This is a standard preliminary earnings disclosure required by the Korea Exchange (KRX) before the final audit report is published. Since it provides key financial highlights and performance drivers rather than the full annual report, it is classified as an Earnings Release (ER). FY 2025
2026-02-26 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing from HLB Therapeutics regarding the 'Acquisition of Convertible Bonds before Maturity'. It details the specific terms of the bond (16th series), the acquisition amount, the reason (Put-Option exercise), and the method of disposal (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding bond acquisition, it fits best under the 'Capital/Financing Update' category.
2026-01-02 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the administrative procedure for determining shareholder eligibility. Given its nature as a regulatory notification of a corporate event, it fits best under the RNS category.
2025-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.